Caris Life Sciences, Inc.
$15.63 +$0.11 (+0.71%) 1D After hoursKey Metrics
The Story So Far
LAST 6 MONTHS PRIMARY SOURCES ONLY-
Jul 16
Money rotated out of high-beta cohorts market-wide.
High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.
RECEIPT: ROTATION GAUGE, LIVE -
May 15
From its Feb 2 high, the share price fell 38%.
Peak close $23.32 on Feb 2; trough close $14.55 on May 15. The drawdown is the fact — the chapters around it are the context.
RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -38% -
May 13
The stock moved -12.4% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, May 13 -
May 8
The stock moved -18.6% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, May 8
The story updates itself as events post · The wolf reports; you decide
Snapshot
About Caris Life Sciences, Inc.
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
Wolf Grade COMING SOON
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.